Over the past decade, the production of angiotensin-converting enzyme (ACE) inhibitor drug intermediates has become increasingly important in the pharmaceutical industry. The most significant clinical application of ACE inhibitors is in the management of hypertension and cardiovascular diseases, particularly congestive heart failure (CHF). A number of chemical methods have been reported thus far for the synthesis of ACE inhibitor precursors. However, chemical methods generally suffer from process complexity, high cost, and environmental pollution. On the other hand, enantiomerically pure ACE inhibitor drug precursors can be obtained elegantly and efficiently by employing biocatalytic methods, where it appears to be the most attractive process in terms of potential industrial applications and green chemistry. In the recent past, membranes are expeditiously used in the enzyme-catalyzed synthesis of optically active pharmaceutical compounds on laboratory and industrial scales, being incorporated in membrane bioreactor system. This technique can be applied for the repeated use of the enzymes in the synthesis via retention or immobilization, especially when dealing with costly biocatalysts. Herein we review the enzymatic synthesis of vital ACE inhibitor drug precursors as potentially useful intermediates in the synthesis of pharmaceutical products, in environmentally friendly condition, using membrane bioreactor for biotransformation.
INTRODUCTION
Over the last 20 years, angiotensin-converting enzyme (ACE) inhibitors have achieved widespread usage as one of the first line drugs for treatment of hypertension and congestive heart failure [1] [2] [3] . ACE inhibitors have long been the cornerstone for therapy of cardiovascular disorders, chronic heart failure, hypertension, left ventricnlar dysfunction as well as prevention of nephropathy in diabetes mellitus. Recent clinical trials have shown that ACE inhibitors are superior to other classes of drugs in the reduction of morbidity and mortality [4] , hence establishing its importance in the pharmacentical industry.
Virtually all ACE inhibitors with therapeutic
Corresponding author: A. L. Ahmad (email: chlatif@eng.usm. my) significance such as enalapril, delapril, lisinopril, quinapril, ramipril, trandolapril, cilazapril and benzapril ( Figure 1 ) [5, 6] , refer to (S)-2-amino-4-phenylbutanoic acid and (R)-2-hydroxy-4-phenylbutanoic acid or their esters as a common building block, due to the presence of (S)-homophenylalanine moiety as the central pharmacophore unit [7] .
Thus far, there exist many conceivable methods of producing enantiomerically pure ACE inhibitor drug precursors, more commonly via chemical [8, 9] , microbial or enzymatic routes by way of kinetic resolution or asymmetric synthesis. Chemical methods generally suffer from process complexity, high cost, and environmental pollution. [17] , with a maximum theoretical yield of 50% [18] . Asymmetric synthesis involves the enantioselective conversion of prochiral substrates to an optically active product, contributing to a theoretical yield of 100%. Thus, a cursoryappraisal of the relativeeconomics racemate resolution versus asymmetric synthesis indicates a preference for the latter since it has a theoretical yield of 100%. Besides that, racemate resolution also has a major setback as it requires at least one extra step to racemize the unwanted isomer for production of enantiopure intermediates [7, 19, 20] . Although various solutions were developed in the scientific community to overcome this drawback including dynamic resolution by in situ racemization [21] , the process often incur extra cost, thus further favoring asymmetric synthesis which are normally applied for pharmaceuticals synthesis using membrane bioreactors.
BIOTRANSFORMATION FOR ACE INHIBITOR DRUG INTERMEDIAfE PRODUCTION
Relationships between, and co-existence of, membranes and biocatalysts is ubiquitous throughout nature. Thus, before we delve into the production of ACE inhibitor drag precursors using a membrane bioreactor, herein' 'we provide a prefatory review of the biocatalytic procedures generally used for their synthesis. Asymmetric reduction of prochiral ketone remains one of the most investigated methods to date for production of chiral ACE inhibitor intermediates, as mentioned in the previous section. Many successful advances have been published thus far, with reproducible results of satisfactory yield. One 01 the most established method for synthesizing ACE inhibitor drug precursor, namely (S)-2-arnino-4-phenylbutanoic acid and (R)-2-hydroxy-4-phenylbutanoic acid on a laboratory scale was carried out via enzyme-catalyzed asymmetric synthesis of keto acids [22, 23] . In this method, prochiral ketone was converted via reductive amination to enantiopure products [24] with bulky side chains by addition of biocatalysts such as Lhomophenylalanine dehydrogenase [25J or Dlactate dehydrogenase in the presence of cofactor. Since the coenzyme is expensive, an efficient and cost-effective in situ regeneration of the compound is prerequisite in order to meet the economic constraints [26] . For this reaction, NADH was regenerated in parallel using formate dehydrogenase which catalyzes the oxidation of formate to CO 2 with the concomitant reduction of NAD to NADH [27] [28] [29] . The equilibrium of the reaction is very favorable as the byproduct CO 2 which is not obnoxious to the drug precursors can be easily removed. The equilibrium 01 the enzyme-catalyzed reaction with cofactor regeneration strongly favors the ACE inhibitor intermediate synthesis therefore high conversion could be obtained, especially if a membrane bioreactor module is employed as will be discussed in the subsequent section. Another enzyme-catalyzed method involves the facile synthesis of (S)-2-amino-4-phenylbutanoic acid, an ACE inhibitor intermediate, which was successfully accomplished with sufficient yield by Chen and colleagues [30J. In this work, genetically engineered tyrosine-aminotransferase-catalyzed synthesis was carried out for production of drug intermediate. Genetically engineered tyrosine aminotransferase is produced by overexpressing the gene product in Escherichia Coli,and generally has an enzymatic activity of approximately 109.8 unit! rnl in the culture media. It is noted that any commercially produced genetically engineered tyrosine aminotransferase are equally applicable. (S)-2-amino-4-phenylbutanoic acid which precipitates easily from the solution under reaction conditions could be produced in high yield and enantiomeric excess in a laboratory-scaled unit.
Besides that, (S)-2-amino-4-phenylbutanoic acid was also produced by using microbial cells containing aminotransferase activity as reported by Senuma, Cho and coworkers [31, 32] . Senuma and coauthors successfully prepared ACE inhibitor drug precursor with high yield using Paracoccus denitriiicans. Cho and collegues also synthesized the compound asymmetrically using a recombinant aromatic amino acid transaminase in the reaction media which permits efficient synthesis of ACE intermediates using a single transaminase reaction. Nevertheless, the aminotransferase activity is markedly inhibited by a high concentration of substrate in the reaction mixture leading to limitations in large-scale production.
Hydantoinase processes have newly been established by Kao [33] for production of (S)-2-amino-q-phenylbutanoic acid using recombinant
Escherichia coli cells with dihydropyrimidinase
and L-N-carbamoylase activities as whole cell biocatalysts which are thermostable for a substantial duration under the reaction conditions used. However, further study is needed to develop the desired enzyme with substrate preference to the (S) enantiomer in order to improve the achieved yield.
In a research work published by de Lacerda and colleague [12, 34] , potential tools for the desired biotransformation to acquire (R) -2-hydroxy-i-phenylbutyrate, a key intermediate in the production of ACE inhibitors was investigated.
Various microorganisms indudingKluyveromyces marxianus,Pichia pastoris, Pichiaanomala and
Pichia angusta were used in the experiment, where high conversion and enantioselectivity was ultimately obtained by utilization of P angusta. The product was synthesized via microbial reduction in an aqueous medium, thus established an attractive process in terms of potential industrial application and green chemistry.
Alternatively, immobilized whole cells of Proteus vulgaris can be used for the production of (R)-2-hydroxy-4-phenylbutanoic acid [5] . The asymmetric reduction of 2-oxo-4-phenylbutanoic acid ethyl ester to the corresponding (R) -2-hydroxy-d-phenylbutanoic acid ethyl ester was likewise investigated by Chadha [35] . The biotransformation procedure was carried out by cell cultures of Daucus carota, producing a high yield and enantiomeric excess of the product. The adopted method obviates the problem of racemate mixture resolution, as only enantiopure product was produced.
ACE INHIBITOR DRUG PRECURSOR SYNTHESIS USING MEMBRANE BIOREACTOR WITH POTENTIAL INDUSTRIAL APPLICATION
Production of ACE inhibitor intermediates has been studied for many years, as discussed in the previous section [12, 19, 22, 25, [30] [31] [32] [33] [34] [35] catalysts, effectively retaining them in soluble form while allowing transport of substrates and products to and from the homogeneous solution [37] . In such circumstances, by exploiting the advantages of combining membranes and biocatalysts, membrane bioreactors with conventional reaction and product separation units [5J, have been engineered to produce various ACE inhibitor drug precursors with high selectivity and productivity under mild conditions. Production of the ACE inhibitor intermediates are generally carried out in a continuously operated stirred tank reactor with an additional membrane separation unit to retain the enzymes either in their free soluble state or immobilized onto the membrane. For the production of (R)-2-hydroxy-4-phenylbutanoic acid as one of the drugs intermediates, one of the successfully published methods involve the usage of D-lactate-NAD oxidoreductase as the solubilized enzyme for the enzymatic reduction redox reaction in aqueous solution. A bioreactor equipped with a detached ultrafiltration membrane separation unit is used for production of the precursor, with regeneration of cofactor by a coupled reaction system [38] [39] [40] [41] . This system could simultaneously be adopted for the production of the (S)-2-amino-4-phenylbutanoic acidcounterpart, using L-homophenylalanine dehydrogenase as the appropriate enzyme [42, 43] . Membrane unit operations usually workunder mildconditions and areenvironmental safe processes [44], as depicted in the synthesis of ACE inhibitor intermediates with low working temperature and pressure, with the additional advantage of minimum diffusional resistancedue to directcontactbetween substrate and biocatalyst [45] .
In contrast to this situation, membrane bioreactors are also employed for immobilizationof enzymes or whole cells to provide high retention of enzymeactivity, high ratesof masstransfer, ease of enzyme replacement and for the latter, an environment for increasedcell densities to obtain higher product yield. The enzymes or cells are retained in the bioreactor through a membrane barrier, and the membrane bioreactors could be configured in microcapsule, hollow fiber or flat sheet reactor modules, each with their respective pros and cons [46] . The hollow fiber and flat sheet membrane bioreactors could also be applied for the synthesis of ACE inhibitor drug precursors where whole cells could be immobilized on the membrane for better yield.
Although membrane bioreactors have gained widespread application, the development of compact and integrated one-unit-joint-application meliorated bioreactors with efficient enzyme retention system for drug intermediate production has remained by and large uncharted, with ample room for innovation. With respect to this context, enhanced performance bioreactors particularly integrated membrane bioreactors could be utilized for economicallycompetitive and practicable largescale drug precursor production process. This technology has emerged as a result of advances made in the areas of membrane technology for wastewater treatment, but remained largely unexplored in the production of pharmaceutical intermediates. The system usually makes use of a reactor module, coupled to a separation unit for the continuousremoval of products while retaining the biocatalysts. It is projected that the use of integrated membranes in the system would generate a more effective and efficient process. The substrates and the coenzyme NAD could be pumped through a sterile filter into the membrane bioreactor, with the product leaving the membrane bioreactor through an ultrafiltration membrane with varying molecular weight cut off for different enzymes. Enzymes are to be supplemented periodically dependent on the deactivation rates via a sterile filter to the membrane bioreactor. It is of significance to note that this reduction process could be optimized, with room for improvement particularly in the amount of buffer,water and solvent used.
CONCLUSION
The number of possibilities for integrating the membrane bioreactor seems to be vast, bearingin mind that the cost of pharmaceuticals production has become one of the prominent factors for production of single enantiomers. The integrated retrofit system offers numerous advantages including a compact design with small footprint, low system and operating cost, and complete enzyme removal in a single unit. Although ACE inhibitor precursors have been produced industrially, the large scale technology is still at an emerging stage. The key-point to success is the process of transferring the laboratory procedures into cost-effective and reliable plant scale operation, in which the design of integrated membrane bioreactor usurps a significantrole, thus sufficient knowledge should be generated for their ultimate development. 
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